Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
793.18
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years
August 06, 2024
Eli Lilly is one of the most innovative pharmaceutical companies right now.
Via
The Motley Fool
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
August 06, 2024
These tried-and-true businesses can deliver returns to investors for many years to come.
Via
The Motley Fool
Decoding Eli Lilly's Options Activity: What's the Big Picture?
August 05, 2024
Via
Benzinga
Should You Buy Eli Lilly Before Aug. 8?
August 05, 2024
There's reason to be optimistic about what's to come.
Via
The Motley Fool
What's Going On With Eli Lilly Today?
July 30, 2024
Eli Lilly & Co shares are trading lower Tuesday. Here's what you need to know.
Via
Benzinga
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Large Cap Biopharma And Healthcare, A Port In A Storm
August 05, 2024
Healthcare and biopharma show nice gains in a volatile week.
Via
Talk Markets
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
August 05, 2024
Eli Lilly's Zepbound and Novo Nordisk's Wegovy face supply shortages, influencing doctors' prescribing habits. Both companies are investing heavily to meet demand in the lucrative U.S. market.
Via
Benzinga
After Ozempic And Botox, Hollywood Is Going Gaga Over This New Anti-Aging Supplement
August 05, 2024
This trend is gaining momentum although its effectiveness is yet to be determined.
Via
Benzinga
THQ: A Favorite Pharma Fund
August 04, 2024
Medical spending is set to rise as an increasing proportion of the US population crosses the retirement age. Spending is projected to grow an average of 5.6% a year through 2032. The abrdn Healthcare...
Via
Talk Markets
Topics
Retirement
Exposures
Pension
These 2 Simple ETFs Could Turn $500 a Month Into $1 Million.
August 04, 2024
Learn how $500 a month can grow into a sizable nest egg.
Via
The Motley Fool
Topics
ETFs
Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?
August 04, 2024
Recent results from a clinical trial show that treatment with Zepbound significantly reduced patients' risk of heart failure outcomes, including cardiovascular death.
Via
The Motley Fool
3 Unstoppable Stocks to Buy in August
August 03, 2024
It's not hard to envision how all three of these stocks can deliver exceptional growth.
Via
The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
August 03, 2024
These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market.
Via
The Motley Fool
Is This Decision by Pfizer Bad News for Eli Lilly?
August 03, 2024
Lilly's revenue gains have helped its stock to roar higher.
Via
The Motley Fool
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
August 02, 2024
Psychologists warn of increased eating disorders linked to popular GLP-1 weight loss drugs like Wegovy and Zepbound. Experts urge better screening and research to address potential risks.
Via
Benzinga
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
August 02, 2024
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin improved significantly due to reduced costs and higher selling prices....
Via
Benzinga
What's Going On With Eli Lilly and Company Shares Friday
August 02, 2024
Eli Lilly is anticipated to release earnings on August 8 for the 2024 fiscal year second quarter.
Via
Benzinga
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
August 02, 2024
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users.
Via
Investor's Business Daily
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
August 02, 2024
The innovative biotech is looking for its next blockbuster.
Via
The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.
Via
The Motley Fool
Why Eli Lilly Stock Trounced the Market on Thursday
August 01, 2024
What's good for Zepbound is good for the company, it seems.
Via
The Motley Fool
What's Going On With HIMS Shares Today?
August 01, 2024
Hims & Hers Health experienced a significant decline in its stock price on Thursday. Here's what you need to know.
Via
Benzinga
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
August 01, 2024
Anti-obesity therapeutics are all the rage and for good reason. Investors seeking to profit should consider these weight loss stocks.
Via
InvestorPlace
8 Health Care Stocks With Whale Alerts In Today's Session
August 01, 2024
Via
Benzinga
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
August 01, 2024
Eli Lilly's SUMMIT phase 3 trial shows tirzepatide significantly reduces heart failure risk in adults with HFpEF and obesity. Tirzepatide achieved primary and secondary endpoints, including improved...
Via
Benzinga
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
August 01, 2024
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth.
Via
The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
August 01, 2024
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term.
Via
The Motley Fool
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
July 31, 2024
Investors should consider the long term prospects of the following three healthcare stocks as the U.S. population ages.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.